European schizophrenia drug market is estimated to grow at a CAGR of 1.5%, during the forecast period (2024-2031). The market growth is driven by the increasing number of mental health disorders. Additionally, the government policies in the region for mental health promote market growth. The European schizophrenia drug market is segmented by therapeutic class (second-generation antipsychotics, […]
